TAP1 and prostate adenocarcinoma: The expression of TAP1 was increased in 25 cancers, including Glioblastoma Multiforme (GBM), Brain Lower Grade Glioma (LGG), Breast invasive carcinoma (BRCA), Kidney renal papillary cell carcinoma (KIRP), Colon adenocarcinoma (COAD), Prostate adenocarcinoma (PRAD), KIRC, and so on, while decreased in Adrenocortical carcinoma (ACC).